Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for Haemonetics (HAE) over the last 6 years, with Q4 2025 value amounting to $14.9 million.

  • Haemonetics' Depreciation and Depletion fell 197.37% to $14.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $61.0 million, marking a year-over-year increase of 252.1%. This contributed to the annual value of $60.0 million for FY2025, which is 752.69% up from last year.
  • Haemonetics' Depreciation and Depletion amounted to $14.9 million in Q4 2025, which was down 197.37% from $15.5 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Depreciation and Depletion ranged from a high of $15.5 million in Q3 2025 and a low of $11.7 million during Q3 2022
  • Over the past 4 years, Haemonetics' median Depreciation and Depletion value was $14.6 million (recorded in 2024), while the average stood at $14.2 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 1367.52% in 2023, then crashed by 197.37% in 2025.
  • Quarter analysis of 4 years shows Haemonetics' Depreciation and Depletion stood at $13.1 million in 2022, then grew by 8.4% to $14.2 million in 2023, then grew by 7.04% to $15.2 million in 2024, then fell by 1.97% to $14.9 million in 2025.
  • Its Depreciation and Depletion stands at $14.9 million for Q4 2025, versus $15.5 million for Q3 2025 and $15.4 million for Q2 2025.